Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shouvik Dass

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|January 31, 2022
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated VasculitisJack Arnold, Edward M Vital, Shouvik Dass, et al.
Annals of the Rheumatic Diseases|April 10, 2015
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisionsMd Yuzaiful Md Yusof, Edward M Vital, Sudipto Das, et al.
ACR Open Rheumatology|June 6, 2022
Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren SyndromeSophanit Pepple, Jack Arnold, Edward M Vital, et al.
Rheumatology (Oxford, England)|February 18, 2020
Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasisMd Yuzaiful Md Yusof, Kundan Iqbal, Michael Darby, et al.
Rheumatology (Oxford, England)|August 1, 2024
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trialsJack Arnold, Lucy M Carter, Md Yuzaiful Md Yusof, et al.
Arthritis and Rheumatism|May 28, 2011
B cell biomarkers of rituximab responses in systemic lupus erythematosusEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Rheumatology (Oxford, England)|January 12, 2021
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritisAndrew R Melville, Md Yuzaiful Md Yusof, John Fitton, et al.
Rheumatology (Oxford, England)|March 10, 2022
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximabJack Arnold, Shouvik Dass, Sarah Twigg, et al.
Rheumatology (Oxford, England)|June 26, 2025
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapyJohn Fitton, Andrew Melville, Andrea Di Matteo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2019
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal DiseasesMd Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|January 31, 2022
A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated VasculitisJack Arnold, Edward M Vital, Shouvik Dass, et al.
Annals of the Rheumatic Diseases|April 10, 2015
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisionsMd Yuzaiful Md Yusof, Edward M Vital, Sudipto Das, et al.
ACR Open Rheumatology|June 6, 2022
Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren SyndromeSophanit Pepple, Jack Arnold, Edward M Vital, et al.
Rheumatology (Oxford, England)|February 18, 2020
Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasisMd Yuzaiful Md Yusof, Kundan Iqbal, Michael Darby, et al.
Rheumatology (Oxford, England)|August 1, 2024
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trialsJack Arnold, Lucy M Carter, Md Yuzaiful Md Yusof, et al.
Arthritis and Rheumatism|May 28, 2011
B cell biomarkers of rituximab responses in systemic lupus erythematosusEdward M Vital, Shouvik Dass, Maya H Buch, et al.
Rheumatology (Oxford, England)|January 12, 2021
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritisAndrew R Melville, Md Yuzaiful Md Yusof, John Fitton, et al.
Rheumatology (Oxford, England)|March 10, 2022
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximabJack Arnold, Shouvik Dass, Sarah Twigg, et al.
Rheumatology (Oxford, England)|June 26, 2025
Neither ultrasound synovitis nor clinical-ultrasound phenotypes of established rheumatoid arthritis predict response to targeted therapyJohn Fitton, Andrew Melville, Andrea Di Matteo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 28, 2019
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal DiseasesMd Yuzaiful Md Yusof, Edward M Vital, Damien M McElvenny, et al.
Pageof 3